The role of complement in experimental autoimmune myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 1274, Issue 1, 2012, Pages 127-132

  Kusner, Linda L ^a   Kaminski, Henry J ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Autoimmunity; C5; Complement; Complement regulators; Myasthenia gravis

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C9; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; ECULIZUMAB; IMMUNOGLOBULIN G; MEMBRANE COFACTOR PROTEIN; REGULATOR PROTEIN; REV 576; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CELL SURFACE; DIAPHRAGM MUSCLE; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; EXPERIMENTAL MODEL; EXTRAOCULAR MUSCLE; LYSIS; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOPHYSIOLOGY;

EID: 84871329671     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06783.x     Document Type: Article

References (27)

1. Sahashi, K. et al. 1978. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol. 37: 212-223.
2. Sahashi, K. et al. 1980. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39: 160-172.
3. Nakano, S. & A.G. Engel. 1993. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 43: 1167-1172.
4. Lennon, V.A. et al. 1978. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J. Exp. Med. 147: 973-983.
5. Tsujihata, M. et al. 2003. Effect of myasthenic immunoglobulin G on motor end-plate morphology. J. Neurol. 250: 75-82.
6. Soltys, J. et al. 2009. Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann. Neurol. 65: 67-75.
7. Zhou, Y. et al. 2007. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J. Immunol. 179: 8562-8567.
8. Biesecker, G. & C.M. Gomez. 1989. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142: 2654-2659.
9. Piddlesden, S.J. et al. 1996. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71: 173-177.
10. Engel, A.G. et al. 1977. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52: 267-280.
11. Selcen, D. et al. 2004. Are MuSK antibodies the primary cause of myasthenic symptoms Neurology 62: 1945-1950.
12. Romi, F. et al. 2005. The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J. Neuroimmunol. 158: 191-194.
13. Barohn, R.J. & R.L. Brey. 1993. Soluble terminal complement components in human myasthenia gravis. Clin. Neurol. Neurosurg. 95: 285-290.
14. Ashizawa, T. & S.H. Appel. 1985. Immunopathologic events at the endplate in myasthenia gravis. Springer Semin. Immunopathol. 8: 177-196.
15. Wallis, R. et al. 2010. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology 215: 1-11.
16. Engel, A.G. et al. 1979. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor. Neurology 29: 179-188.
17. Chamberlain-Banoub, J. et al. 2006. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin. Exp. Immunol. 146: 278-286.
18. Tuzun, E. et al. 2003. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171: 3847-3854.
19. Christadoss, P. 1988. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140: 2589-2592.
20. Roversi, P. et al. 2007. The structure of OMCI, a novel lipocalin inhibitor of the complement system. J. Mol. Biol. 369: 784-793.
21. Navenot, J.M. et al. 1997. Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Muscle Nerve 20: 92-96.
22. Kaminski, H.J. et al. 2004. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp. Neurol. 189: 333-342.
23. Kusner, L.L. et al. 2012. Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve DOI: 10.1002/mus.23448.
24. Tuzun, E. et al. 2006. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J. Neuroimmunol. 181: 29-33.
25. Morgan, B.P. et al. 2006. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin. Exp. Immunol. 146: 294-302.
26. Kaminski, H.J. et al. 2006. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp. Neurol. 202: 287-293.
27. Song, C. et al. 2012. Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis. Muscle Nerve 45: 668-675.